Phase 3 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed through a tissue biopsy to have a type of blood cancer called diffuse large B-cell lymphoma (DLBCL), diagnosed according to standard medical guidelines
• People whose cancer shows up as active on a PET scan (a type of imaging test), scoring 4 or 5 on a standard 5-point scale
• People who have not yet received any treatment for their DLBCL
• People who are generally able to carry out daily activities, as measured by a standard medical scoring system (rated 0 to 2 out of 5), assessed within 7 days before joining the trial
• People whose heart is pumping at 45% efficiency or above, as measured by a heart ultrasound or a specific heart scan
• People living with HIV, provided their HIV is well managed with medication
• People who have hepatitis B, provided they are on antiviral treatment and the virus is undetectable in their blood before joining the trial
• People with a history of hepatitis C, provided the virus is undetectable in their blood at the time of screening

Who may not be able to join:

• People whose DLBCL developed from a slower-growing (indolent) lymphoma that transformed into this more aggressive type
• People diagnosed with a related but different type of lymphoma called primary mediastinal B-cell lymphoma or Grey zone lymphoma
• People whose DLBCL is classified as Stage I (the earliest, most localised stage) according to a standard staging system
• People with serious heart or blood vessel conditions, including a stroke or heart attack within the past 6 months, unstable chest pain, significant heart failure, or a serious irregular heartbeat requiring medication
• People with significant fluid buildup around the heart or lungs
• People experiencing ongoing nerve problems (such as tingling, numbness, or weakness) that are moderate or worse in severity
• People who have a specific inherited nerve condition called Charcot-Marie-Tooth disease (the demyelinating form)
• People living with HIV who have also had Kaposi's sarcoma or a condition called Multicentric Castleman's Disease
• People currently taking corticosteroid medications (such as prednisone)
• People who have received a live vaccine within 30 days before starting the trial (non-live/killed vaccines are permitted)
• People who have or have had another cancer that is still active or has required treatment within the past 2 years
• People with lymphoma that has spread to the brain or spinal cord (central nervous system)
• People with an autoimmune disease that has required whole-body treatment within the past 2 years
• People with an active infection that requires medication to treat
• People who have both active hepatitis B and active hepatitis C at the same time
• People who have previously received an organ or tissue transplant from another person

Important: Always verify eligibility with the trial site directly before applying.